[SharePad] Screening For My Next Long-Term Winner: Fuller, Smith & Turner

***ShareScope New Subscriber Special Offer***
Readers of my blog can enjoy a 20% first-year discount! Click here for details >>

10 September 2020
By Maynard Paton

First, a wealth warning.

The last price-to-book ‘bargain’ I looked at for SharePad was Hammerson.

Back then investors were in theory able to purchase £1 of assets for just 30p. The share price has since lost 75%.

A few tweaks to the same stock screen now leads me to Fuller, Smith & Turner. 

This pub group has suffered during the pandemic, but sleuthing via SharePad reveals substantial freehold assets that the balance sheet may significantly undervalue. 

This property backing may limit further downside as the group re-opens its pubs and aims to recover.

Read my full Fuller, Smith & Turner article for SharePad.

Maynard Paton

MINCON: H1 Dividend Disappointingly Deferred Yet Bumper ‘Geotech’ Sales Help Profit Gain Up To 28% And Perhaps Support A Reasonable 14.3x P/E

21 August 2020
By Maynard Paton

Results summary for Mincon (MCON):

  • A generally satisfactory update given the pandemic, with underlying revenue up almost 5% and profit before adjustments perhaps up as much as 28%.
  • The postponement of the interim dividend due to Covid-19 was disappointing after earlier statements barely mentioned the virus.
  • An emphasis on “geotechnical” drills and services has reduced the dependence on mining customers to 52% of revenue. 
  • Modest cash generation, average margins and enormous stock levels offer significant scope for accounting improvements during the current ‘moat-rebuilding’ phase.  
  • Various (perhaps optimistic) assumptions alongside opportunities from new products lead to a reasonable 14.3x P/E. I continue to hold.

Read more

Mountview Estates:  FY 2020 Statement Signals Modest 8% Gearing, ’Happy’ Auction-Room Activity And Potential To Pick Up Possible Pandemic Property Bargains

13 August 2020
By Maynard Paton

Results summary for Mountview Estates (MTVW):

  • Standstill 2020 figures that showed 8% more properties sold at prices 9% lower than last year.
  • A maintained dividend, a lack for furloughed staff and the directors currently being “happy in the auction room” underline some pandemic-resilient qualities. 
  • Net debt representing a very modest 8% of the group’s property estate suggests significant scope to pick up any property bargains.
  • This week’s AGM witnessed a further bout of protest votes against the independent non-executives, the board’s pay and the auditors.
  • MTVW’s book value increased by 3% to a record £97 per share, although my calculations suggest the balance sheet could be worth £200-plus per share. I continue to hold.

Read more

[SharePad] Screening For My Next Long-Term Winner: Fever-Tree Drinks

***ShareScope New Subscriber Special Offer***
Readers of my blog can enjoy a 20% first-year discount! Click here for details >>

29 July 2020
By Maynard Paton

They say mums always know best.

Mine has bought Fever-Tree tonic waters for some years now and I recently asked whether she remained a customer. This was her response.

“While we don’t buy many commercial drinks for home consumption these days I would still definitely buy Fever-Tree, generally the original tonic water. I went into an actual shop (M&S) last week for the first time and spotted the selection of Fever-Tree drinks. I was tempted at the time but as the weather was poor decided against it.

If we were having visitors it would definitely be purchased. When going out with certain knowledgeable friends for lunch etc, Fever-Tree is always the drink of choice. If the cafe/restaurant doesn’t sell Fever-Tree it is ‘downgraded’ on our rating and generally abandoned. Availability of Fever-Tree is, to us, a sign of caring about quality.”

I had no idea mum regarded the drinks so highly. If she is representative of every Fever-Tree customer, then maybe the company deserves our attention.

Read my full Fever-Tree Drinks article for SharePad.

Maynard Paton

[SharePad] Screening For My Next Long-Term Winner: Headlam

***ShareScope New Subscriber Special Offer***
Readers of my blog can enjoy a 20% first-year discount! Click here for details >>

19 July 2020
By Maynard Paton

Let me start by thanking you for showing interest in an article with Headlam in the title.

Rest assured, not everyone will want to read about this rather dull business that has suffered badly during the pandemic.

But for us contrarians, now may be the time to consider such stocks — unloved names that the market rebound has left far behind.

Headlam seems to possess the industry position, balance-sheet strength and management experience to survive this downturn and recover thereafter. A full share-price recovery could even offer a potential 100% gain.

Read my full Headlam article for SharePad.

Maynard Paton

System1: 2021 Recovery Hopes Seem Dependent Upon ITV And (Bizarrely) 18th Century German Literature Following Profit Crash, Scrapped Dividend And AdRatings Write-Off

17 July 2020
By Maynard Paton

Results summary for System1 (SYS1):

  • Somewhat academic annual figures that showed pre-AdRatings profit down 27% due to weak trading prior to Covid-19.
  • The pandemic has since caused demand for SYS1’s services to drop 38% and created pre-tax losses.
  • AdRatings continues to generate minimal revenue at significant cost, although the tie-up with ITV suggests the fledgling service has some inherent value.
  • SYS1 bizarrely remains very poor at marketing its own services. A flagship company film commences with references to 18th century German literature. 
  • A £3.9m cash buffer ought to keep SYS1 afloat as it moves towards more reliable revenue sources. Valuation in the meantime remains anyone’s guess. I continue to hold.

Read more

Tasty: Radical Management Action Urgently Required As Estimated Pandemic Cash Burn Could Leave Company Broke By November

01 July 2020
By Maynard Paton

Results summary for Tasty (TAST):

  • Largely redundant annual figures that revealed revenue down 6% and another operating loss.
  • TAST’s 56 restaurants were shut in March and my estimates suggest the group could survive without sales until November.
  • The second half seemed encouraging after Christmas bookings were helped by a turkey-themed festive menu.
  • A £2m property disposal bolstered cash and cleared debt but significant liabilities remain.
  • The £2.8m market cap could be a bargain, but radical management action is now essential to keep the business afloat. I continue to hold.

Read more

Q2 2020: 10 Lessons From A 10-Bagger

30 June 2020
By Maynard Paton

I trust your shares have recovered during the last three months.

A quick summary of my portfolio’s second-quarter and year-to-date progress:

  • Q2 gain: +7.8%*
  • Q2 trades: None.
  • YTD loss: -0.9%* (FTSE 100: -16.9%**)
  • YTD winners/losers: 3 winners vs 9 losers  

(*Performance calculated using quoted bid prices and includes all dealing costs, withholding taxes, broker-account fees and paid dividends. **Includes reinvested dividends)

I am thankful the news from my shares during Q2 was relatively positive. In particular, four of my holdings declared dividends — which seems encouraging given the numerous payout suspensions witnessed of late. 

Mind you, I did not escape the dividend cancellations entirely. One of my shares sadly scrapped its payout after admitting the pandemic had led to weaker sales and operating losses.

Just how the market will fare from here is impossible to say. I did not buy during the March lows and remain 25% in cash… so I am naturally hoping the bargains have not dried up just yet!

Read more

Andrews Sykes: FY 2019 Results Admit 50% Of UK Staff Are Furloughed Although Management Talks Of “Resilient” Trading And Even Declared A Final Dividend

16 June 2020
By Maynard Paton

Results summary for Andrews Sykes (ASY):

  • Creditable full-year figures that showed revenue down 2% and profit down 7% due to less extreme weather. 
  • The decision to furlough 50% of UK staff feels odd given management talks of “resilient” trading, kept company depots open during lockdown and has declared a final dividend.
  • A commendable cash flow projection raises pandemic-profitability questions but suggests extra funding is not needed.
  • An impressive second half ensured the accounts remained healthy with high margins and an appealing return on equity.  
  • A possible P/E of 12-14 and yield of 4.5% does not seem expensive if indeed ASY does “return to normal levels of trading” for 2021. I continue to hold.

Read more

[SharePad] Screening For My Next Long-Term Winner: Frontier Developments

***ShareScope New Subscriber Special Offer***
Readers of my blog can enjoy a 20% first-year discount! Click here for details >>

11 June 2020
By Maynard Paton

Has the market become too obsessed with ‘pandemic-proof’ shares?

I ask because my SharePad screening has brought Frontier Developments to my attention.

The shares of this computer-game developer have leapt 66% so far this year as industry sales rally during the lockdown.

However, Frontier’s accounting looks rather questionable and the near-£800 million market cap seems completely mad. Yet nobody seems to mind given the company’s apparent resilience to Covid-19.

Read my full Frontier Developments article for SharePad.

Maynard Paton

PS: I have also compared Frontier’s accounting to that of Team17 and Codemasters.

PPS: I have provided further Frontier observations on the Quidisq forum.

M Winkworth: Q1 2020 Dividend Overshadows Foxtons-Beating 2019 Figures And Hints At Better-Than-Expected Pandemic Progress

31 May 2020
By Maynard Paton

Results summary for M Winkworth (WINK):

  • Acceptable full-year figures that showed revenue up 8% and profit up 12% following an encouraging second half.
  • The declaration of a Q1 dividend for 2020 implies possible resilience to Covid-19 and hints at a better-than-expected pandemic performance.
  • Very impressive market-share gains continue to be won from London rival Foxtons.
  • Despite a number of accounting niggles, the books remain in pretty good shape with high margins and net cash.
  • A possible P/E of 8-12 and a potential income of 6% may offer upside should earnings revive and then one day thrive following Brexit, stamp-duty changes and Covid-19. I continue to hold.

Read more

FW Thorpe: Immediate Covid-19 Problems Prevented After £47m Net Cash Allows 2% H1 Dividend Lift And Commendable Refusal Of Government Assistance

18 May 2020
By Maynard Paton

Results summary for FW Thorpe (TFW):

  • Acceptable 7-9% first-half growth, although profitability has essentially stalled for the last 2-3 years as the LED mini-boom subsides.
  • A 2% dividend lift, net cash and investments of £47m, a “strong” order book plus an outstanding response to government assistance do not imply immediate Covid-19 problems.
  • However, trading is not perfect, as margins at the largest division continue to decline while overseas cross-selling progress remains slow and small. 
  • The SmartScan light-monitoring system could be a ‘hidden gem’, with sales up 50% last year to represent 20% of total revenue.
  • A P/E of 22-25 feels warm, but may reflect the ‘pandemic-proof’ balance sheet, SmartScan potential and/or resilient profit history. I continue to hold.

Read more

[SharePad] Screening For My Next Long-Term Winner: Hikma Pharmaceuticals

***ShareScope New Subscriber Special Offer***
Readers of my blog can enjoy a 20% first-year discount! Click here for details >>

14 May 2020
By Maynard Paton

One way to invest during the pandemic is to consider shares that have climbed higher as the market has dropped.

Such companies may well be ‘safe havens’ — businesses that are coping well with the lockdown, or perhaps even benefitting from the crisis.

I applied the following simple criteria within SharePad to identify potential ‘pandemic-proof’ names:

  • A share-price change this year of 0% or more;
  • A market cap of £250 million or more, and;
  • A profit of £1m or more.

On my shortlist was Hikma Pharmaceuticals, which has rallied 17% so far this year. Other attractions included:

  • An appealing 22% margin and 19% return on equity;
  • Profit being twice the level of debt;
  • A forecast 18x P/E not appearing too extreme, and;
  • The directors owning a useful shareholding.

Read my full Hikma Pharmaceuticals article for SharePad.

Maynard Paton

Bioventix: 34x P/E Understandably Reflects ‘Pandemic-Proof’ Outlook As H1 Dividend Lifted 20% And Margins Hit 80%

01 May 2020
By Maynard Paton

Results summary for Bioventix (BVXP):

  • Very satisfactory 26% first-half profit growth led by continued demand for the group’s vitamin D antibody.
  • A 20% dividend lift alongside presentation references to broker forecasts were very reassuring given the current Covid-19 uncertainty.
  • The fledgling troponin product seems to have gained momentum while an emerging pollution-biomonitoring project offers intriguing long-term potential.
  • Despite a part-time FD and an accounting error, the books remain in excellent shape with terrific 80% margins, a notable cash buffer and no debt.
  • The seemingly ‘pandemic-proof’ outlook leaves the valuation remaining understandably rich with an underlying P/E of 34. I continue to hold.

Read more

S & U: Final 2020 Dividend And No Furloughed Staff Underline Management Confidence Of ‘Non-Prime’ Customers Repaying Loans Totalling £302m

19 April 2020
By Maynard Paton

Results summary for S & U (SUS):

  • Another set of record annual figures that showed steady progress — albeit overshadowed entirely by the potential impact of Covid-19.
  • The boardroom’s confidence is encouraging. The final dividend was reduced only slightly and no staff have been furloughed.
  • Some £302m has been loaned to customers with patchy credit histories, and recouping that money has become vital. Management says collections are “very good”.
  • Net debt of £118m and a 26% net-interest margin lead to respectable returns on capital, but the borrowings will not prove ideal if defaults increase and profits fall.
  • Current-year earnings have become anyone’s guess, and a bargain-basement P/E may be rather less than the current 10x trailing multiple. I continue to hold.

Read more

ABOUT ME

Investing in shares for 25+ years. Former share tipster. ShareScope evangelist. Blogger. Webhost nerd. FIRE | Read more | Contact

PORTFOLIO

Holdings and buy prices. Latest trades. Quarterly updates. Annual returns from 2012. Purchases from 2004 | Read more

SHARESCOPE

The most comprehensive and best value all-in-one research and data service for private investors | Special blog offer

BLOG POST ALERTS

A simple link to every new blog post. No spam!

© maynardpaton.com 2025 • Disclaimer • Privacy • Contact